There is evidence suggesting a positive effect of cigarette smoking on myocardial tissue reperfusion and clinical outcomes in patients with myocardial infarction ('smoker's paradox'). We aimed to evaluate the relationship of smoking with cardiac magnetic resonance (CMR)-determined myocardial salvage and damage as well as clinical outcomes in patients undergoing primary percutaneous coronary intervention (PPCI) for ST-elevation myocardial infarction (STEMI).
Introduction
Cigarette smoking is a major risk factor for acute coronary thrombosis leading to myocardial infarction. 1 Despite the deleterious effects of smoking on cardiovascular health, some studies suggested the existence of a 'smoker's paradox', meaning a survival benefit in smokers vs. non-smokers with acute myocardial infarction. 2 -8 The favourable outcome in smokers was observed even after accounting for differences in baseline risk features. It has therefore been speculated that smokers might have improved myocardial salvage, less extensive myocardial necrosis, and less impairment of microvascular function. 9 -12 However, several other studies have questioned the existence of this paradox. 13 -19 Cardiac magnetic resonance (CMR) imaging is nowadays regarded as the reference standard for the visualization and quantification of myocardial injury in patients with ST-elevation myocardial infarction (STEMI). 20 In addition, the salvaged myocardium at risk and the status of the microvasculature can be assessed with high accuracy. 21 Consequently, CMR allows unique insights into the potential relationship of smoking status with myocardial damage after mechanical reperfusion for acute STEMI. Moreover, emerging evidence has demonstrated that CMR parameters of myocardial damage are strongly related with poor outcomes after acute STEMI. 22 -24 So far, no studies have addressed whether there are differences in CMR-determined infarct characteristics and subsequently outcome between smokers and non-smokers undergoing contemporary reperfusion with primary percutaneous coronary intervention (PPCI) for acute STEMI. Therefore, this study sought (i) to investigate the relationship of smoking status with myocardial salvage and irreversible ischaemic injury assessed by CMR and (ii) to determine the prognostic significance of smoking status on clinical outcome among STEMI patients.
Methods

Study design
This multicentre CMR study was a predefined substudy of the AIDA STEMI trial (Abciximab Intracoronary vs. Intravenous Drug Application in ST-Elevation Myocardial Infarction). AIDA STEMI was a randomized, open-label, multicentre trial, comparing the effects of intracoronary vs. standard intravenous bolus application of abciximab in patients with STEMI undergoing PPCI. 25 The design and principal results of AIDA STEMI as well as those of the CMR substudy were published previously. 22,25 -27 In brief, consecutive STEMI patients presenting ,12 h after symptom onset were screened for study participation. The CMR substudy included 795 patients and found no difference in CMR markers of myocardial damage and reperfusion injury between both groups. 27 Smoking status was prospectively questioned by a structured interview at admission, and patients were categorized as current smokers, nonsmokers, and ex-smokers (stop of smoking ≥6 months ago). The clinical endpoint of the CMR substudy was the incidence of major adverse cardiac events (MACEs), defined as a composite of all-cause death, nonfatal re-infarction, and new congestive heart failure at 12 months after infarction. Detailed endpoint definitions are reported elsewhere. 25, 27 The local Ethics Committee approved the study, and patients were required to provide written informed consent.
CMR imaging
Patients underwent CMR imaging on a 1.5 or 3.0 T scanner [Siemens Magnetom Verio (3 T), Siemens, Germany; Siemens Avanto (1.5 T), Siemens; Siemens Symphonie (1.5 T), Siemens; Phillips Intera, CV (1.5 Tesla), Philips Medical Systems, The Netherlands; GE Signa Excite (1.5 T), General Electric, USA] between days 1 and 10 after infarction. The standardized imaging protocol and post-processing have been described elsewhere. 25, 27 Cine sequences were used for the measurement of left ventricular (LV) function and volumes, T2-weighted imaging for the assessment of the area at risk (AAR), and late enhancement imaging for the determination of infarct size (IS) and microvascular obstruction (MVO). Image analysis was performed by a blinded CMR core laboratory (University of Leipzig-Heart Center, Leipzig, Germany). Reproducibility and inter-as well as intra-observer variabilities of the CMR core laboratory were reported previously. 28 The measurements of AAR, IS, and MVO were expressed as the percentage of LV volume (% LV). 23, 29 Myocardial salvage index (MSI) was quantified from AAR and IS as described previously. 30 
Statistical analysis
One hundred and thirty-four ex-smokers and 254 non-smokers were subsumed into one group. This is motivated by the fact that they have nearly identical time-to-event curves. Furthermore, the analysis becomes much simpler and clearer. Distribution of data was tested with the use of the Shapiro -Wilk test. Categorical variables are depicted as frequencies with corresponding percentage. Continuous variables are presented as mean + standard deviation or median with interquartile range, according to their distribution. Differences between groups were tested with Student's t-test, Mann-Whitney U-test, or x 2 test as indicated. Overall and MACE-free survival was estimated and depicted by Kaplan-Meier methods. Multiple Cox models with one to two variables for overall and with four to five variables for MACE-free survival were built to adjust for possible confounders. We selected the most associated variables by means of the LASSO method. 31 This algorithm is first able to select variables without using P-values. Secondly, one can force the number of variables by changing the model parameter lambda. All tests were two-tailed, and the significance level is 0.05. The LASSO procedure was performed by the R package. All other statistical analyses were performed by means of SPSS Statistics 22.0.0 (IBM, Armonk, NY, USA).
Results
Patient characteristics
Smoking status was available in 727 patients (91.4%) ( Figure 1 ). Of these, 339 (46.6%) were current smokers and 388 (53.4%) were non-smokers or ex-smokers. Baseline patient characteristics are shown in Table 1 . Smokers were significantly younger (P , 0.001), more often men (P , 0.01), and had a lower body mass index (P , 0.01). Hypertension (P , 0.001), diabetes mellitus (P , 0.001), previous PCI (P ¼ 0.05), and anterior infarction (P ¼ 0.05) were more prevalent in non-smokers. Consequently, the TIMI-risk score was higher in non-smokers compared with smokers (P , 0.001). TIMI flow before and after PPCI was not significantly different between both the groups (both P ¼ 0.49 and 0.67, respectively).
Smoking and infarct characteristics
Patients underwent CMR imaging 3 (2-4) days after infarction in both the groups (P ¼ 0.74). Table 2 provides an overview on infarct characteristics and their association with smoking status. The extent of the AAR (P ¼ 0.10) and IS (P ¼ 0.21) was similar between the groups. Consequently, there was no difference in MSI (P ¼ 0.47). The occurrence and amount of MVO were not significantly different between smokers and non-smokers (P ¼ 0.97 and 0.91, respectively). Similarly, intramyocardial haemorrhage was not significantly different between smokers and non-smokers (P ¼ 0.58). LV ejection fraction was also similar between smokers and non-smokers (P ¼ 0.48).
Smoking and clinical outcome
All patients completed 12-month follow-up. Forty-five patients (6.2%) experienced a MACE during follow-up. Of these 18 patients died (2.5%). Smokers had significantly lower MACE (3.8 vs. 8.5%, P ¼ 0.01) and mortality (0.9 vs. 3.9%, P ¼ 0.01) rates when compared with non-smokers. Accordingly, smoking status was a significant predictor of MACE [hazard ratio (HR) ¼ 0.46, 95% confidence interval (CI) 0.24 -0.88, P ¼ 0.02] and mortality (HR ¼ 0.23, 95% CI 0.07 -0.79, P ¼ 0.02) in univariate Cox regression analysis. However, multivariate adjustment for baseline risk factors attenuated the association of smoking status with MACE and death markedly ( Table 3) . No significant multiple association of smoking with death could be proved after adjustment by TIMI risk score (HR ¼ 0.48, 95% CI 0.14 -1.73, P ¼ 0.26). This score aggregates the predictive ability of some baseline risk factors, including age, heart rate, blood pressure, body weight, Killip class, diabetes, hypertension, time to treatment, and anterior STEMI. A patient with one point above (that is, e.g. age 75 against 65 years or additionally hypertension) is associated with increased risk for death by factor 1.7.
Similarly, significant association of smoking with MACE could no more be demonstrated [HR ¼ 0.71 (0.36-1.38), P ¼ 0.31] after adjustment by number of diseased vessels and TIMI risk score. Two or three diseased coronary arteries double the risk for MACEs when compared with patients with only one diseased vessel. The corresponding unadjusted and adjusted survival graphs for MACE are shown in Figure 2 . Regarding CMR parameters, LV ejection fraction (HR ¼ 0.93, 95% CI 0.91-0.96, P , 0.001), IS (HR ¼ 1.03, 95% CI 1.01-1.06, P , 0.01), and MVO (HR ¼ 1.08, 95% CI 1.01 -1.16, P ¼ 0.02) were confirmed to be significant predictors of MACE.
Discussion
This large CMR multicentre study evaluated for the first time, in a contemporary cohort of STEMI patients treated with PPCI, the effect of admission smoking status on the salvaged myocardium at risk and irreversible myocardial damage as well as its prognostic significance for MACE and mortality at 12 months after infarction. The major findings are as follows: (i) the amount of myocardial salvage and the extent of myocardial necrosis and microvascular injury were similar between smokers and non-smokers and (ii) smokers were at lower risk for MACE and mortality at 12 months; however, this association did not remain significant after adjustment for baseline risk features.
Thus, this study complements the previous literature by demonstrating that the more favourable prognosis of smokers is not explained by differences in myocardial salvage or irreversible myocardial damage, but rather by a more favourable baseline risk profile of smokers. Our findings, therefore, challenge the existence of a smoker's paradox.
Smoking status and baseline characteristics in STEMI
Cigarette smoking has negative effects on multiple hemostatic processes leading to an imbalance of antithrombotic and prothrombotic factors, thereby stimulating the initiation and propagation of coronary artery disease and coronary thrombosis. 1 Owing to the strong prothrombotic effects, smokers more often present with STEMI than with non-STEMI. 32 In smokers, STEMI occurs approximately one decade earlier than in non-smokers. 16 In accordance with younger age, there is consistent evidence that smokers have Continued less comorbidities compared with non-smokers presenting with STEMI. 13 -16,19 In line with these observations, smokers were significantly younger in our study and had a lower prevalence of hypertension and diabetes mellitus as well as a trend for less hypercholesterolaemia. Additionally, we found that non-smokers were more likely to have anterior infarctions and tended to have more often triple vessel disease, findings that have been also reported in previous trials. 16 Importantly, these differences in baseline risk are well-known predictors of adverse prognosis after STEMI. 33 -35 Thus, the unadjusted differences in survival and MACE in smokers vs. non-smokers are most likely related to disparities in baseline risk and clinical characteristics.
Smoking status, infarct characteristics, and clinical outcomes in STEMI
In contrast to the overwhelming data for the harmful health consequences of cigarette smoking, there is conflicting evidence regarding the association of smoking and clinical outcome after infarction. A number of studies reported a more favourable prognosis in smokers sustaining acute STEMI. 2 -8 Although the aforementioned differences in baseline risk characteristics partly explained these observations, some authors found that smoking status remained a significant predictor of clinical events even after multivariate adjustment. The vast majority of data favouring this smoker's paradox was, however, generated in the pre-thrombolytic and thrombolytic era. Moreover, several other investigations evaluating the prognostic significance of smoking status on clinical outcome did not find an independent association between smoking and clinical events when considering clinical risk characteristics. 13 -19 The pathophysiological mechanisms behind the potential relationship between smoking status and adverse outcome are also controversial, and studies investigating this issue are scarce. Some recent studies suggested that smoking might be related to increased myocardial salvage, smaller infarcts, and less damage to the microvasculature of the myocardium and subsequently to a more favourable clinical outcome in patients with STEMI. 9 -12 These studies were, however, mainly single-centre observations and evaluated only small sample sizes. More importantly, they used angiographic, electrocardiographic, or biochemical approaches to determine myocardial salvage, IS, and microvascular function. The use of these methods has several limitations, and none of these studies applied CMR imaging, which is nowadays the reference technique for the quantification of myocardial injury after reperfused STEMI. 23, 36 Our study is the first using CMR for the assessment of smokingspecific reperfusion therapy efficacy. The current study clearly shows that the salvage of myocardium at risk as well as the extent of myocardial and microvascular injury as visualized by CMR is not different between smokers and non-smokers undergoing PPCI for acute STEMI. Likewise, smoking status was not predictive of MSI or MVO in multiple linear regression analysis. Thus, our study highlights that PPCI efficacy (myocardial salvage) and restoration of tissue perfusion are similar in smokers vs. non-smokers presenting with acute STEMI. Despite the similarities in infarct characteristics, smokers were at lower risk for MACE and mortality at 12 months after infarction. These associations were nearly entirely explained by the differences in age and comorbidities, as smoking status was no longer significantly associated with clinical events after multivariate adjustment.
The different results between studies favouring a smoker's paradox vs. ours and others questioning this paradox remain unclear. It has been hypothesized that reperfusion by thrombolysis might be more effective in smokers due to a greater thrombus burden than in non-smokers. 6 This benefit might no longer exist when using contemporary mechanical reperfusion strategies. This explanation is underlined by the fact that the smoker's paradox has been demonstrated almost entirely in the pre-PCI era. It was also speculated that residual confounding due to incomplete adjustment for baseline characteristics might explain the positive effects of smoking in some studies. 37 
Limitations
This study has several limitations. Information on smoking status was only available on admission. The potential impact of changes in smoking habits after the index event might affect clinical event rate and could not be assessed in this study. Moreover, former smokers and pack years were not identified in the current study, making a more detailed differentiation between patients not possible. Further studies are necessary to address these important issues. CMR scans were available only at admission precluding the assessment of adverse LV remodelling in the current study. Longitudinal CMR studies evaluating the course of post-infarction remodelling and the potential impact of smoking habits on this process would be of interest as well. Finally, inclusion and exclusion criteria might limit generalization of study results.
Conclusions
This study demonstrates no relationship between smoking status and CMR parameters of myocardial salvage, extent of infarction, and microvascular injury among STEMI patients treated with contemporary mechanical reperfusion. Smokers had more favourable unadjusted 1-year clinical outcomes than non-smokers; however, these differences were entirely explained by differences in age and comorbidities. Thus, our results challenge the existence of a smoker's paradox in STEMI patients.
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